Article Text
PDF
Abstract
Introduction/Background Thrombocytosis is frequently encountered in cancer patients and is believed to be the result of increased platelet production. Pretreatment thrombocytosis has been addressed by numerous researchers as a predisposing factor of reduced patient survival. To date, the impact of postoperative thrombocytosis following splenectomy has not been evaluated and in the present study we sough to investigate its potential correlation.
Methodology The study was based on a retrospective chart review of ovarian cancer patient records that had splenectomy as a part of their debulking procedure between 2016 and 2021. All patients that had maximal effort cytoreductive procedures (Surgical complexity score >4) were considered eligible. Thrombocytosis was considered as a platelet count >500.000 per μL. The progression free and overall survival rate was considered from the onset of diagnosis until the timing of disease recurrence and/or death respectively. The level of significance for all analyses was set to p<.05.
Results Overall, 82 women were included in the present study. Of those, 8 women had optimal tumor resection (<1 cm lesions remaining) while the rest had complete tumor resection (no visible tumor). Fifty-one patients had primary debulking, 17 women had interval debulking and 14 women had secondary debulking surgery. Thrombocytosis was observed in 52 patients (63%). Sixty-five recurrences and thirty-one deaths were noticed during this period. Pretreatment thrombocytosis did not influence the recurrence rates (p=.451) or death rates (p=.520) of studied patients. Moreover, the progression free survival was comparable among splenectomized patients with thrombocytosis and those without (26 months vs 24 months p=.683). Similarly, the overall survival was also similar among the two groups (39 months vs 47 months, p=.511). No differences were observed among subgroups according to the timing of the procedure (PDS, IDS or secondary debulking).
Conclusion Post-splenectomy thrombocytosis does not seem to alter survival outcomes of ovarian cancer patients.
Disclosures The authors report no conflicts of interest.
